These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 18093264)
1. Qualification of biomarkers for drug development in organ transplantation. Burckart GJ; Amur S; Goodsaid FM; Lesko LJ; Frueh FW; Huang SM; Cavaille-Coll MW Am J Transplant; 2008 Feb; 8(2):267-70. PubMed ID: 18093264 [TBL] [Abstract][Full Text] [Related]
2. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Shapiro R; Scantlebury VP; Jordan ML; Vivas CA; Jain A; Hakala TR; McCauley J; Johnston J; Randhawa P; Fedorek S; Gray E; Chesky A; Dvorchik I; Donaldson J; Fung JJ; Starzl TE Transplant Proc; 2002 Aug; 34(5):1651-2. PubMed ID: 12176521 [No Abstract] [Full Text] [Related]
3. Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report. Mannon RB; Morris RE; Abecassis M; Axelrod D; Bala S; Friedman GS; Heeger PS; Lentine KL; Loupy A; Murphy B; Nickerson P; Sarwal M; O'Doherty I; Spear N; Karpen SR Am J Transplant; 2020 Jun; 20(6):1495-1502. PubMed ID: 32090461 [TBL] [Abstract][Full Text] [Related]
4. Current concepts and perspectives of immunosuppression in organ transplantation. Scherer MN; Banas B; Mantouvalou K; Schnitzbauer A; Obed A; Krämer BK; Schlitt HJ Langenbecks Arch Surg; 2007 Sep; 392(5):511-23. PubMed ID: 17450373 [TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in solid organ transplantation: an update. Shapiro R Transplant Proc; 1999 Sep; 31(6):2203-5. PubMed ID: 10500545 [No Abstract] [Full Text] [Related]
7. Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions. Christians U; Klawitter J; Klawitter J; Brunner N; Schmitz V Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):175-200. PubMed ID: 21241200 [TBL] [Abstract][Full Text] [Related]
8. Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period. Ishibashi M; Miyamoto S; Nojima M; Yoshimoto T; Yabumoto H; Mori Y; Shima H Transplant Proc; 1999 Nov; 31(7):2761-2. PubMed ID: 10578281 [No Abstract] [Full Text] [Related]
9. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function. Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289 [No Abstract] [Full Text] [Related]
10. Surrogate biomarkers of long-term outcome after kidney transplantation. Paul LC Ann Transplant; 2000; 5(2):5-6. PubMed ID: 11217207 [No Abstract] [Full Text] [Related]
11. A novel scale of immunosuppression exposure and correlation to outcomes after renal transplantation. Morrissey PE; Gohh RY; Monaco AP Transplant Proc; 2002 Aug; 34(5):1640-1. PubMed ID: 12176517 [No Abstract] [Full Text] [Related]
12. Factors associated with long-term renal allograft survival. Kaplan B; Srinivas TR; Meier-Kriesche HU Ther Drug Monit; 2002 Feb; 24(1):36-9. PubMed ID: 11805720 [TBL] [Abstract][Full Text] [Related]
13. Living donor renal transplantation--experience with 50 patients in 5 years. Wolters HH; Vowinkel T; Brockmann J; Palmes D; Heidenreich S; Dietl KH Transplant Proc; 2002 Sep; 34(6):2216. PubMed ID: 12270370 [No Abstract] [Full Text] [Related]
14. [Research in transplant immunology in kidney transplantation]. Tan JM Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(10):649-50. PubMed ID: 15932722 [No Abstract] [Full Text] [Related]
15. Overview of clinical trials with new agents. Charpentier B; Hiesse C; Durrbach A; Ammor M; Von Ey F; Kechrid C; Kriaa F Transplant Proc; 2001 May; 33(3):2201-3. PubMed ID: 11377502 [No Abstract] [Full Text] [Related]
16. How to handle mycophenolate mofetil in combination with tacrolimus? Braun F; Canelo R; Schütz E; Shipkora M; Lorf T; Hanack U; Niedmann D; Armstrong VW; Oellerich M; Ringe B Transplant Proc; 1998 Dec; 30(8):4094-5. PubMed ID: 9865309 [No Abstract] [Full Text] [Related]
17. Microemulsion cyclosporine postmarketing surveillance in renal transplant recipients: multicenter study in Korea. Korean Neoral Study Group Transplant Proc; 2000 Nov; 32(7):1473-6. PubMed ID: 11119794 [No Abstract] [Full Text] [Related]
18. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials. Schnitzler MA; Lentine KL; Axelrod D; Gheorghian A; You M; Kalsekar A; L'Italien G Transplantation; 2012 Jan; 93(2):172-81. PubMed ID: 22198496 [TBL] [Abstract][Full Text] [Related]
19. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study. Opelz G Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253 [No Abstract] [Full Text] [Related]
20. [Cyclosporin in transplantation management--especially after kidney transplantation]. Quellhorst E Internist (Berl); 1996 Jan; 37(1):88-90. PubMed ID: 8837834 [No Abstract] [Full Text] [Related] [Next] [New Search]